EyePoint Pharmaceuticals Announces Yutiq Presentations at AAO Annual Meeting

Source: EyePoint Pharmaceuticals

EyePoint Pharmaceuticals announced that two abstracts supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year microinsert for chronic, noninfectious uveitis affecting the posterior segment of the eye have been accepted for presentation at the American Academy of Ophthalmology (AAO) 2019 annual meeting being held October 12–15, 2019 in San Francisco. One abstract was accepted for oral presentation at the Retina Subspecialty Day program of AAO on October 11, 2019.

“Feedback received from uveitis specialists and patients as part of our ongoing U.S. commercial launch of Yutiq continues to reinforce the treatment limitations of corticosteroids for chronic, noninfectious uveitis affecting the posterior segment of the eye,” Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals, said in a company news release. “We believe Yutiq provides a highly differentiated product profile compared to existing therapies due to its convenient office administration and consistent dosing for up to 36-months. Additional data to be shared at AAO provide further evidence of the long-lasting activity of Yutiq for this difficult to treat ocular disease that can lead to blindness.”

Details for AAO presentations are as follows:

Oral Presentation 

Title: Effect of Fluocinolone Acetonide Insert on the Presence of Uveitic Macular Edema: Outcomes at 36 Months
Presenter: Quan Nguyen, M.D., M.Sc., Professor of Ophthalmology, Byers Eye Institute, Stanford University
Session Title: RET08 – Section V: Uveitis, Retina Subspecialty Day
Date and Time: Friday, October 11, 2019; 1:58-2:05 PM PDT

Poster Presentation 

Title: PO532 Fluocinolone Acetonide Intravitreal Insert for Noninfectious Posterior Uveitis: Analysis of Significant IOP Elevation
Presenter: Michael Singer, M.D., Clinical Professor of Ophthalmology, University of Texas Health Science Center
Session Title: PD40 – ePoster Discussion: Uveitis
Date and Time: Monday, October 14, 2019; 12:30-1:30 PM PDT
Panel Discussion Time: 1:00 – 1:30 PM PDT



Related Content